UTILITY therapeutics Ltd. Announces Financing Led by the AMR Action Fund and FDA Acceptance of PIVYA New Drug Application with Priority Review

UTILITY has received a Prescription Drug User Fee Act (PDUFA) target action date of April 24, 2024FDA granted Qualified Infectious Disease Product (QIDP) designation for PIVYA in 2018, which provides an additional 5 years of data exclusivity upon appro…

UTILITY therapeutics Ltd. Announces Financing Led by the AMR Action Fund and FDA Acceptance of PIVYA New Drug Application with Priority Review Read More

IMPORTANT INVESTOR NOTICE: The Schall Law Firm Encourages Investors in VNET Group, Inc. with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / January 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against VNET Group, Inc. (“VNET” or “the Company”) (NASDAQ:VNET) for v…

IMPORTANT INVESTOR NOTICE: The Schall Law Firm Encourages Investors in VNET Group, Inc. with Losses to Contact the Firm Read More

Südzucker AG Announces Start of Acceptance Period for Public Delisting Tender Offer to Shareholders of CropEnergies AG

Offer document published following approval by BaFin.Acceptance period commences today and ends on February 16, 2024; there will be no additional acceptance period.Opportunity for all CropEnergies shareholders to tender their shares at an attractive ca…

Südzucker AG Announces Start of Acceptance Period for Public Delisting Tender Offer to Shareholders of CropEnergies AG Read More